UW-Madison researchers have developed methods for preparing PTP1b-deficient neutrophils, which exhibit improved recruitment and antimicrobial functions. The inventors employed CRISPR/Cas9 to delete PT...
Learn More

Clostridium botulinum produces the lethal botulinum neurotoxin (BoNT). There are several types of BoNT, and the subtype BoNT/A1 is used medically to treat muscle movement disorders and cosmetic concer...
Learn More

UW Madison researchers have developed a virus-free, CRISPR-Cas mediated method of generating T cells that target senescent cells. These modified T cells could be used to treat Alzheimer’s Disease an...
Learn More

The present invention relates to a ‘sugar fermentate of edible fungi’ (i.e., cultures of GRAS species from the genus Aspergillus) that exhibits antimicrobial activity (e.g., against Listeria monoc...
Learn More

UW-Madison researchers have developed a series of mutant influenza B viruses that incorporate mutations in the HA1 protein that cause the virus to react with sera generated via exposure to the opposit...
Learn More

UW-Madison researchers have developed a dendron-micelle (DM) nanoparticle platform that can be used for combination therapy in the treatment of interstitial lung disease (ILD), including idiopathic pu...
Learn More

UW-Madison researchers have developed methods for generating SIRPα-KO macrophages with superior anti-tumor activity, and SIRPα-knockout neutrophils with superior anti-bacterial and anti-tumor activi...
Learn More

Theranostics, a term derived from a combination of therapeutics and diagnostics, is an emerging field of medicine where specific radionuclide disease-targeting agents are used to diagnose and treat me...
Learn More

UW-Madison researchers have identified novel ACE2 mutants having enhanced activity and/or specificity in hydrolyzing angiotensin II. ACE2 (angiotensin converting enzyme 2) is a key metalloprotease of ...
Learn More

The present invention relates to novel IBV vaccines containing novel modified S and N antigens from avian coronaviruses. The modifications include: S has a modified transmembrane domain for better sec...
Learn More

The present invention relates to a novel bivalent coronavirus/influenza virus vaccine (called CoroFlu). The vaccine comprises a coronavirus antigen (a secreted version of the spike (S) protein of SARS...
Learn More

The present technology from UW Madison inventors provides nanoparticles comprising a positively charged polymer (e.g., polylysine) electrostatically bound to iron oxide nanoparticles and CpG oligodeox...
Learn More

UW-Madison researchers have developed a novel fusion protein for inducing Breg cell formation and a method for transforming any human B cell into an IL10-competent, functional Breg cell ex vivo at sca...
Learn More

UW-Madison researchers successfully developed and demonstrated improved mRNA stabilization techniques that leverage mineral coatings. In short, the inventors stabilized mRNA complexes on mineral coate...
Learn More

UW-Madison researchers have discovered a novel marker in cardiac fibroblasts and myofibroblasts that reliably predicts extracellular matrix production in cultured cardiac fibroblasts. Sushi Domain Con...
Learn More

UW Madison researchers and collaborators have developed anti-SARS-CoV-2 α/β-polypeptides, pharmaceutical compositions containing the same, and methods to inhibit, treat, and ameliorate SARS...
Learn More

The inventors have developed a novel system for co-differentiation of hepatocytes and hematopoietic progenitors from human embryonic stem cells (ES cells) that mimics a late fetal liver undergoing hem...
Learn More

The present invention from UW Madison inventors is a set of analogs of turbinmicin that show similar efficacy but are more soluble than the parent molecule. The parent molecule proved to be fairly ins...
Learn More

The present technology from UW Madison innovators provides a composition comprising a mixture of a source of calcium ions, alginate conjugated to an acrylate monomer (ALG-A), carboxymethylcellulose co...
Learn More

The present technology from UW Madison innovators provides a system for monitoring quorum-sensing in bacteria comprising bacteria that release at least one membrane-lytic toxin when the bacteria are a...
Learn More

Ex vivo expansion and activation of T cells are prerequisites for any form of genetically engineered T cell immunotherapy. Several expansion and activation methodologies have been developed. However, ...
Learn More

Use of viral vectors for chimeric antigen receptor (CAR) T cell manufacturing constitutes a bottleneck in the supply chain for biomanufacturing and can be problematic due to: (1) batch-to-batch variab...
Learn More

The present technology from this UW Madison researcher is a germinant mixture that includes a) a bile acid main germinant, b) an amino acid co-germinant, c) an edible spore solubilizing agent, and d) ...
Learn More

The present invention by UW Madison researchers is a method of using enzalutamide, or other AR antagonists, to treat lung inflammation. In working with AR in the lungs, the researchers note that AR do...
Learn More

UW-Madison researchers have isolated and characterized a BA.2 strain of the Omicron variant of SARS-CoV-2.
Learn More